Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TV-44749 (olanzapine ER SC) in adults with schizophrenia
CTR20232834Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olanzapine in schizophrenia (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Started Sep 2023; status: terminated.
02
Drugs
olanzapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20232834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232834.